A new preclinical study has shown that reducing the protein HDAC11 could slow muscle degeneration in Duchenne muscular dystrophy, providing a potential target for future therapies.
A preclinical study led by the Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Institut de Myologie and the Sant Pau Research Institute, has highlighted the role of the protein HDAC11 in Duchenne muscular dystrophy (DMD) and its potential as a target for future therapies.
Understanding Duchenne muscular dystrophy
DMD is a severe genetic condition that progressively deteriorates the muscles. It usually manifests in childhood and worsens steadily throughout life. Currently, there is no cure, and treatment options are limited, focusing mainly on slowing disease progression and improving patients’…